This finding matters to me for a very personal reason. I have described using a product sold as retatrutide, but I cannot independently confirm what it contained. Reading a promising study cannot answer that question for me — or for anyone else.
What was in the tested vial?
On 14 September 2026, the TGA reported that someone had been hospitalised after uncontrolled vomiting caused a torn oesophagus. They had used a product sold as retatrutide.
When the regulator tested a sample from the original unmarked vial, it found semaglutide and no retatrutide. Semaglutide is the active ingredient in Ozempic. That does not mean this was genuine Ozempic.
The amount was approximately eight times the level in the TGA-assessed semaglutide products it compared against. That comparison does not tell us the dose the person actually received, or give anyone a safe way to adjust or use the vial. [1]
What can we be confident about?
The testing came directly from the Australian regulator’s laboratory. That gives me confidence in the reported finding for this sample.
It does not tell us how often other products are counterfeit, confirm another seller’s product, or describe the safety of the medicine used in clinical trials. The laboratory finding and the person’s reported reaction are different pieces of information. [1]
A promising study cannot check a vial
Retatrutide remains investigational and is not TGA-approved. Lilly describes access through its clinical trials, where researchers are still evaluating it. [2]
A shared name on a label cannot establish the same ingredients, amount or manufacturing quality. The TGA’s wider peptide warning also raises questions about contamination and sterility — whether a product is free of germs. A polished website or convincing story cannot settle those questions. [3]
Curiosity deserves honest information
I understand wanting another possibility when the usual answers have not been enough. I do not want this conversation to shame anyone for looking.
I do want us to keep asking two separate questions: what does the research show, and what do we actually know about this product? This alert does not give us a women-specific risk estimate or evidence of benefits for ADHD, migraine or menopause.
If this feels close to home
Australian health authorities advise against using unapproved peptide products. If you have bought or used one, seek advice from a qualified healthcare professional. [3]
Victoria’s health alert advises prompt medical care for unusual or unexpected symptoms. Tell the clinician what you used, when and where it came from, and share packaging or a photograph if you have it. [4]
In an emergency, call 000. For advice about suspected poisoning, call the Poisons Information Centre on 13 11 26, available 24 hours. [4]
Read the original sources
- TGA: counterfeit retatrutide laboratory investigation ↗14 September 2026 · Primary regulator safety advisory. Includes a link for reporting adverse events.
- Lilly: investigational status and clinical-trial access ↗Updated July 2026 · Manufacturer information; the developer has a commercial interest.
- TGA and Chief Medical Officer: unapproved peptide risks ↗19 June 2026 · Joint Australian public-health statement.
- Victorian Department of Health: toxicity alert and getting help ↗19 June 2026 · Separate health alert, included for safety guidance; not the source of the September vial-testing finding.